Literature DB >> 18403766

Recent resurgence of mumps in the United States.

Gustavo H Dayan1, M Patricia Quinlisk, Amy A Parker, Albert E Barskey, Meghan L Harris, Jennifer M Hill Schwartz, Kae Hunt, Carol G Finley, Dennis P Leschinsky, Anne L O'Keefe, Joshua Clayton, Lon K Kightlinger, Eden G Dietle, Jeffrey Berg, Cynthia L Kenyon, Susan T Goldstein, Shannon K Stokley, Susan B Redd, Paul A Rota, Jennifer Rota, Daoling Bi, Sandra W Roush, Carolyn B Bridges, Tammy A Santibanez, Umesh Parashar, William J Bellini, Jane F Seward.   

Abstract

BACKGROUND: The widespread use of a second dose of mumps vaccine among U.S. schoolchildren beginning in 1990 was followed by historically low reports of mumps cases. A 2010 elimination goal was established, but in 2006 the largest mumps outbreak in two decades occurred in the United States.
METHODS: We examined national data on mumps cases reported during 2006, detailed case data from the most highly affected states, and vaccination-coverage data from three nationwide surveys.
RESULTS: A total of 6584 cases of mumps were reported in 2006, with 76% occurring between March and May. There were 85 hospitalizations, but no deaths were reported; 85% of patients lived in eight contiguous midwestern states. The national incidence of mumps was 2.2 per 100,000, with the highest incidence among persons 18 to 24 years of age (an incidence 3.7 times that of all other age groups combined). In a subgroup analysis, 83% of these patients reported current college attendance. Among patients in eight highly affected states with known vaccination status, 63% overall and 84% between the ages of 18 and 24 years had received two doses of mumps vaccine. For the 12 years preceding the outbreak, national coverage of one-dose mumps vaccination among preschoolers was 89% or more nationwide and 86% or more in highly affected states. In 2006, the national two-dose coverage among adolescents was 87%, the highest in U.S. history.
CONCLUSIONS: Despite a high coverage rate with two doses of mumps-containing vaccine, a large mumps outbreak occurred, characterized by two-dose vaccine failure, particularly among midwestern college-age adults who probably received the second dose as schoolchildren. A more effective mumps vaccine or changes in vaccine policy may be needed to avert future outbreaks and achieve the elimination of mumps. Copyright 2008 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18403766     DOI: 10.1056/NEJMoa0706589

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  103 in total

1.  Factors influencing preclinical in vivo evaluation of mumps vaccine strain immunogenicity.

Authors:  B Halassy; T Kurtović; M Brgles; M Lang Balija; D Forčić
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Characteristics of a large mumps outbreak: Clinical severity, complications and association with vaccination status of mumps outbreak cases.

Authors:  C Stein Zamir; H Schroeder; H Shoob; N Abramson; G Zentner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  The rise (and fall?) of parental vaccine hesitancy.

Authors:  Charitha Gowda; Amanda F Dempsey
Journal:  Hum Vaccin Immunother       Date:  2013-06-06       Impact factor: 3.452

4.  Investigation of a mumps outbreak in Mongolia, January to April 2011.

Authors:  Igore Munkhjargal; Jargalsaikhan Selenge; Amarjargal Ambaselmaa; Rentseng Tuul; Purevsuren Delgermaa; Sarankhuu Amarzaya; Jantsansengee Baigalmaa; Barhas Byambajav; Dapeng Luo
Journal:  Western Pac Surveill Response J       Date:  2012-12-12

5.  Comparison of the sensitivity of laboratory diagnostic methods from a well-characterized outbreak of mumps in New York city in 2009.

Authors:  Jennifer S Rota; Jennifer B Rosen; Margaret K Doll; Rebecca J McNall; Marcia McGrew; Nobia Williams; Elena N Lopareva; Albert E Barskey; Amado Punsalang; Paul A Rota; William R Oleszko; Carole J Hickman; Christopher M Zimmerman; William J Bellini
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

6.  Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010.

Authors:  George E Nelson; Annette Aguon; Engracia Valencia; Rita Oliva; Michele Leon Guerrero; Richard Reyes; Anna Lizama; Daryl Diras; Annakutty Mathew; E Jessica Camacho; Moryne-Nicole Monforte; Tai-Ho Chen; Abdirahman Mahamud; Preeta K Kutty; Carole Hickman; William J Bellini; Jane F Seward; Kathleen Gallagher; Amy Parker Fiebelkorn
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

7.  Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011.

Authors:  Anja Takla; Merle M Böhmer; Christina Klinc; Norbert Kurz; Alice Schaffer; Heribert Stich; Petra Stöcker; Ole Wichmann; Judith Koch
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

8.  Characterization of large mumps outbreak among vaccinated Palestinian refugees.

Authors:  Musa Y Hindiyeh; Yair Aboudy; Mahmoud Wohoush; Lester M Shulman; Daniela Ram; Tal Levin; Tamar Frank; Flavia Riccardo; Mohamad Khalili; Elias-Shlash Sawalha; Maysoun Obeidi; Guido Sabatinelli; Zehava Grossman; Ella Mendelson
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

9.  Matched case-control study of effectiveness of live, attenuated S79 mumps virus vaccine against clinical mumps.

Authors:  Chuanxi Fu; Jianhua Liang; Ming Wang
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

10.  Risk factors for mumps at a university with a large mumps outbreak.

Authors:  Angela S Huang; Margaret M Cortese; Aaron T Curns; Rebecca H Bitsko; Hannah T Jordan; Fatma Soud; Jose Villalon-Gomez; Patricia M Denning; Kim A Ens; Gail R Hanson; Gustavo H Dayan
Journal:  Public Health Rep       Date:  2009 May-Jun       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.